FINWIRES · TerminalLIVE
FINWIRES

JPMorgan Adjusts Invesco Price Target to $25 From $30, Maintains Neutral Rating

-- Invesco (IVZ) has an average rating of overweight and mean price target of $26.82, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Price: $25.47, Change: $+0.09, Percent Change: +0.37%

Related Articles

Australia

Lucid Diagnostics Completes $18 Million Direct Offering of Shares

Lucid Diagnostics (LUCD) said Friday that is has completed its underwritten direct offering of 18 million shares at $1 per share.The company said the offering was anchored by a $15 million investment from a "fundamental" institutional investor with support from a large existing shareholder.Lucid said it plans to use the net proceeds for working capital and general corporate purposes.Price: $1.09, Change: $-0.01, Percent Change: -0.46%

$LUCD
Australia

Dover Sees Strong Bookings Growth, Demand Momentum, RBC Capital Markets Says

Dover (DOV) reported a modest Q1 operating beat, with 24% bookings growth and a 1.20x book-to-bill ratio pointing to demand momentum, RBC Capital Markets said in a Thursday note.The firm said bookings strength was broad-based, with all segments posting book-to-bill above 1.10x.RBC highlighted strength in clean energy components, fluid transport, retail fueling, refrigerated door cases, heat exchangers and CO2 refrigeration systems.The firm also said bookings strength suggests upside to Dover's 3% to 5% organic growth guidance. Dover reaffirmed its 2026 adjusted earnings per share guidance of $10.45 to $10.65, and revenue growth outlook of 5% to 7%.RBC raised its price target to $252 from $225, and maintained its sector perform rating on Dover.Price: $229.96, Change: $+1.81, Percent Change: +0.79%

$DOV
Insider Trading

Pharvaris Insider Sold Shares Worth $441,726, According to a Recent SEC Filing

Anne Lesage, Chief Early Development Officer, on April 22, 2026, sold 14,700 shares in Pharvaris (PHVS) for $441,726. Following the Form 4 filing with the SEC, Lesage has control over a total of 213,319 common shares of the company, with 56,450 shares held directly and 156,869 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1830487/000119312526176222/xslF345X05/ownership.xmlPrice: $28.49, Change: $+1.20, Percent Change: +4.40%

$PHVS